ATE319996T1 - Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin - Google Patents

Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Info

Publication number
ATE319996T1
ATE319996T1 AT00981763T AT00981763T ATE319996T1 AT E319996 T1 ATE319996 T1 AT E319996T1 AT 00981763 T AT00981763 T AT 00981763T AT 00981763 T AT00981763 T AT 00981763T AT E319996 T1 ATE319996 T1 AT E319996T1
Authority
AT
Austria
Prior art keywords
mortalin
cure
finding
cancer
interaction domain
Prior art date
Application number
AT00981763T
Other languages
English (en)
Inventor
Renu Chugai Wadhwa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE319996T1 publication Critical patent/ATE319996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00981763T 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin ATE319996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35754599 1999-12-16

Publications (1)

Publication Number Publication Date
ATE319996T1 true ATE319996T1 (de) 2006-03-15

Family

ID=18454687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981763T ATE319996T1 (de) 1999-12-16 2000-12-15 Verfahren zum auffinden eines heilmittels für krebs mit hilfe von interaktionsdomänen von p53 und mortalin

Country Status (6)

Country Link
US (1) US20030087263A1 (de)
EP (1) EP1243923B1 (de)
AT (1) ATE319996T1 (de)
AU (1) AU1891801A (de)
DE (1) DE60026576T2 (de)
WO (1) WO2001044807A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004079368A2 (en) 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
EP1536230A1 (de) * 2003-11-28 2005-06-01 Deutsches Rheuma-Forschungszentrum Berlin Durchflusszytometrischer Partikel-basierter Bindungsassay
JP2006089471A (ja) 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
WO2014057490A1 (en) * 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7445800A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Method of prolonging normal cell life span
EP1287116A2 (de) * 2000-05-17 2003-03-05 Geron Corporation Neural vorläuferzellen
JP2001354564A (ja) * 2000-06-14 2001-12-25 Chugai Bunshi Igaku Kenkyusho:Kk カチオン性ローダシアニン系色素誘導体を有効成分とする、ｍｏｔ−２蛋白質とｐ５３蛋白質の相互作用阻害剤

Also Published As

Publication number Publication date
DE60026576T2 (de) 2007-01-18
US20030087263A1 (en) 2003-05-08
DE60026576D1 (de) 2006-05-04
WO2001044807A1 (en) 2001-06-21
EP1243923A4 (de) 2004-05-06
EP1243923B1 (de) 2006-03-08
AU1891801A (en) 2001-06-25
EP1243923A1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
DE60026576D1 (de) VERFAHREN ZUM AUFFINDEN EINES HEILMITTELS FÜR KREBS MIT HILFE VON INTERAKTIONSDOMÄNEN VON p53 UND MORTALIN
EP2261246A3 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
CY1110549T1 (el) Ικριωματα πρωτεϊνων για μιμητικα αντισωματων και αλλες πρωτεϊνες συνδεσης
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
WO2005111066A3 (en) Polypeptides from non-typeable haemophilus influenzae
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
ATE343788T1 (de) Verfahren zum simultanen nachweis von beiden gliedern eines bindungspaares
DE69819332D1 (de) VERBESSERTE ANTIKÖRPER GEGEN IgE UND VERFAHREN ZUR VERBESSERUNG VON ANTIKÖRPERN
DE60133982D1 (de) Biosensor und verfahren zum analysieren von blutkomponenten
ATE420366T1 (de) ERWEITERTER ßTETHERINGß ANSATZ ZUM SCHNELLEN AUFFINDEN VON LIGANDEN
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DE60318744D1 (de) ZUSAMMENSETZUNG AUF BASIS VON 2-CYANOACRYLAT, VERFAHREN UND MITTEL ZUR EVALUIERUNG DER HuRTUNG DAVON
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
DE58901562D1 (de) Verfahren zur koagulation von lacken und anderen organischen beschichtungen.
DK2090582T3 (da) Bindende molekyler til human faktor VIII- og faktor VIII-lignende proteiner
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE60206173D1 (de) Härtende zusammensetzung und verfahren zum aufbringen von alkydbeschichtungsmaterial damit
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
DE60213900D1 (de) Bolzen und diesen verwendendes Verfahren zum Spannen von Bauteilen
ATE284034T1 (de) Verfahren zum nachweis von protein s
DE69924120D1 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE283068T1 (de) Biologisch wirksame konjugate mit einem reporterrest und verfahren zu dessen nachweis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties